HC Wainwright began coverage on shares of MannKind Corporation (NASDAQ:MNKD) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The firm set a “buy” rating on the biopharmaceutical company’s stock.
Several other equities research analysts have also recently commented on the company. Maxim Group restated a “buy” rating on shares of MannKind Corporation in a research note on Friday, September 1st. Zacks Investment Research cut MannKind Corporation from a “hold” rating to a “sell” rating in a research note on Saturday, August 12th. Finally, ValuEngine cut MannKind Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $0.92.
MannKind Corporation (NASDAQ:MNKD) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.10). The firm had revenue of $2.16 million during the quarter, compared to the consensus estimate of $2.75 million. MannKind Corporation had a net margin of 71.60% and a negative return on equity of 24.93%. During the same quarter in the previous year, the firm posted $0.08 EPS.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/10/11/mannkind-corporation-mnkd-coverage-initiated-by-analysts-at-hc-wainwright.html.
About MannKind Corporation
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
What are top analysts saying about MannKind Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MannKind Corporation and related companies.